1. Home
  2. SWKH vs STXS Comparison

SWKH vs STXS Comparison

Compare SWKH & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • STXS
  • Stock Information
  • Founded
  • SWKH 1996
  • STXS 1990
  • Country
  • SWKH United States
  • STXS United States
  • Employees
  • SWKH N/A
  • STXS N/A
  • Industry
  • SWKH Diversified Financial Services
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SWKH Finance
  • STXS Health Care
  • Exchange
  • SWKH Nasdaq
  • STXS Nasdaq
  • Market Cap
  • SWKH 201.5M
  • STXS 189.8M
  • IPO Year
  • SWKH 1999
  • STXS 2004
  • Fundamental
  • Price
  • SWKH $16.57
  • STXS $2.29
  • Analyst Decision
  • SWKH
  • STXS Strong Buy
  • Analyst Count
  • SWKH 0
  • STXS 2
  • Target Price
  • SWKH N/A
  • STXS $4.50
  • AVG Volume (30 Days)
  • SWKH 10.3K
  • STXS 428.5K
  • Earning Date
  • SWKH 11-14-2024
  • STXS 11-11-2024
  • Dividend Yield
  • SWKH N/A
  • STXS N/A
  • EPS Growth
  • SWKH N/A
  • STXS N/A
  • EPS
  • SWKH 0.84
  • STXS N/A
  • Revenue
  • SWKH $24,725,000.00
  • STXS $25,143,000.00
  • Revenue This Year
  • SWKH N/A
  • STXS $1.16
  • Revenue Next Year
  • SWKH $6.17
  • STXS $55.65
  • P/E Ratio
  • SWKH $19.73
  • STXS N/A
  • Revenue Growth
  • SWKH N/A
  • STXS N/A
  • 52 Week Low
  • SWKH $15.14
  • STXS $1.66
  • 52 Week High
  • SWKH $18.49
  • STXS $3.29
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 55.43
  • STXS 62.20
  • Support Level
  • SWKH $16.50
  • STXS $2.12
  • Resistance Level
  • SWKH $16.81
  • STXS $2.51
  • Average True Range (ATR)
  • SWKH 0.38
  • STXS 0.15
  • MACD
  • SWKH 0.10
  • STXS 0.02
  • Stochastic Oscillator
  • SWKH 72.87
  • STXS 71.93

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Share on Social Networks: